He L. SGLT2 Inhibitor And GLP-1 Receptor Agonist in Type 2 Diabetes Mellitus Patients. Research on Their Cardiovascular Benefits. HSET [Internet]. 2023 Dec. 29 [cited 2026 Jun. 8];74:1717-22. Available from: https://drpress.org/ojs/index.php/HSET/article/view/16046